Catalog No.: PC-22354Not For Human Use, Lab Use Only.
PRMT9 inhibitor LD2 is a specific small molecule PRMT9 inhibitor, inhibits PABPC1 R493 methylation level with IC50 of 0.9 uM in in Molm13s, sparing other PRMTs.
PRMT9 inhibitor LD2 is a specific small molecule PRMT9 inhibitor, inhibits PABPC1 R493 methylation level with IC50 of 0.9 uM in in Molm13s, sparing other PRMTs. LD2 binds PRMT9 (−7.15 kcal mol−1) with greater affinity than the other PRMTs tested. LD2 treatment preferentially inhibited the viability of cancer cells and their protein synthesis. LD2 treatment (2.5 uM) expanded the number of IFN-γ-expressing T cells relative to vehicle controls in AML mononuclear cells (MNCs), without effect on T cell viability. LD2 synergizes with anti-programmed cell death protein 1 in eradicating AML.
